283 results about "Dysostosis" patented technology

This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of Bone Mineral Density (BMD) in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of Bone Mineral Density (BMD) in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of BMD in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of BMD in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising an anti-estrogen agent and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof as described herein.

The invention encompasses compositions, methods, and kits, for fixing bone and/or repairing connective tissue associated with bone using a fenestrated bone screw. In certain embodiments, the invention encompasses a pedicle screw system including a bio-resorbable or implantable capsule containing cement and methods of use thereof for treating, preventing, and managing disorders in osteoporotic patients. In certain embodiments, the invention encompasses a fenestrated pedicle screw with cement containment skin that is useful in treating subjects in need of spine surgery due to neurologic deficit, deformity, or trauma, which subjects do not have sufficient time for the medical treatment of osteoporosis.

The present invention relates to methods and materials used to express an HBM-like polypeptide derived from HBM, LRP5 or LRP6 in animal cells and transgenic animals. The present invention also relates to transgenic animals expressing the HBM-like polypeptides. The invention provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development and lipid modulation. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis.

The invention relates to a medicine compound for treating osteoporosis and osteoporosis fracture, which comprises the following components by weight: 30 g of rhizoma drynariae, 25 g of radices dipsaci, 15 g of radices polygoni multiflori, 22 g of turtleback, 20 g of herba epimedii, 9 g of woodlouse, 10 g of native copper, 20 g of red sage root, 15 g of safflower, 12 g of radices paeoniae alba, 9 g of radix clematidis, 10 g of fructus cnidii, 12 g of lignum millettiae, 30 g of angelica, 20 g of astragalus root, 22 g of Chinese yam, 12 g of tuckahoe, 20 g of prepared rhizome of rehmannia, 15 g of antler glue, 15 g of rhizoma cibotii, 12 g of achyranthes, 10 g of cortex eucommiae, 9 g of ossa draconis, 15 g of fructus ligustri lucidi, 10 g of fructus psoraleae, 12 g of atractylodes ovata, 12 g of semen melo, 15 g of elder, 15 g of medlar, 10 g of rhizoma homalonemae, 25 g of cuttle-bone, 8 g of frankincense, and 8 g of myrrh. The medicine compound is suitable for osteoporosis, low in cost, and remarkable in treatment effect, and has a board application prospect.

The invention relates to novel inulin products and compositions thereof, to their manufacture, to their use for modifying and modulating the bacterial flora and the fermentation pattern of inulin in the large intestine of humans, mammals or other vertebrates, to their use for providing improved inulin-associated nutritional effects/benefits, as well as to their use for the manufacture of consumer products and compositions for providing said effects/benefits in healthy, disfunctioned and diseased humans, mammals and other vertebrates. The novel inulin products consist of a particular mixture of an easily fermentable inulin (EFI) component and a hardly fermentable inulin (HFI) component. The nutritional effects/benefits include dietary fibre effects, improved mineral absorption, particularly calcium and magnesium, bone mineral density increase, reduction of bone mineral density loss, modulation of lipid metabolism, stimulation of the immune system, and anti-cancer effects. The novel inulin products are particularly suitable for the manufacture of a composition or a medicament for preventing, for postponing and/or for treating osteoporosis in humans, particularly in post-menopausal women and elderly people.

A calcium phosphate cement with the function of controlling medicine release for repairing dysostosis, treating osteomyelitis and preventing infection and recurrence of osteoma is prepared from porous calcium phosphate cement and medicine capsules containing antibacterial medicine, antineoplastic medicine, anti-flammatory antalgic medicine, antituberculosis, etc. Its advantages are slow medicinesreleasing, and high curative effect.

A method Is disclosed for fully automated segmentation of human vertebral body images in a CT (computerized tomography) study with no user interaction and no phantoms, which has resiliency to, anatomical abnormalities, and protocol and scanner variations. The method was developed to enable automated detection of osteoporosis in CT studies performed for other clinical reasons. Testing with 1.044 abdominal CTs from multiple sites, resulted in detection of 96.3% of the vertebral, bodies and 1% false positives. Of the detected vertebral bodies, 83.3% were segmented adequately for sagittal plane quantitative evaluation of vertebral, fractures indicative of osteoporosis. Improved results were observed when selecting the best sagittal plane of 3 for each vertebra, yielding a segmentation success rate of 85.4%. The method is preferably implemented in software as a building block in a system for automated osteoporosis detection.

The present invention relates to the use of modulators of the sclerostin: sclerostin-binding-partner interaction for the treatment, amelioration, and diagnosis of sclerostin-related disorders, e.g., osteoporosis and sclerosteosis, and sclerostin-related disorders, e.g., cancers and cardiovascular disorders. The invention also relates to the use of sclerostin-binding-partner mimetics for the treatment amelioration, and diagnosis of sclerostin-related disorders. Assays for the identification of modulators of the sclerostin: sclerostin-binding-partner interaction, as well as the resulting signaling, are also provided.

A method for pain treatment and measurement according to various aspects of the present invention generally includes providing an external field to a portion of a living being, wherein the external field comprises a frequency of about 3040 Hz. This frequency of about 3040 Hz can also be intermixed with two or more other frequencies for the treatment and measurement of pain, and can be utilized alone or together with other intermixed frequencies to treat inflammation and osteoporosis.

Extracts of various species of the Leguminosae family have estrogenic properties. For example, aqueous and ethanolic extracts of Pueraria lobata Willd. Ohwi of the Leguminosae family species possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effects include estrogen response element (ERE) stimulation as well as tumor necrosis factor (TNF) repression. Methods are provided for treating climacteric symptoms, breast and/or uterine cancer, and osteoporosis.

This invention provides compounds of Formula (I), having the structurewhere T, Z, X, A, R<1>, R<2a>, R<2b>, R<2c>, R<3>, R<4>, and n are defined herein, or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of osteoporosis and polycystic kidney disease.

The invention relates to a health-cared preparation for improving the osteoporosis of middle and old aged women, and a preparation method thereof. The method mainly takes calcareous compounds such as soy isoflavones and calcium carbonate, eucommia bark or folium cortex eucommiae, psoralea fruit, calcium absorption accelerator, for example, caseinophospho peptides or vitamin D3, and bone joint protective agents, for example, chondroitin sulfate or D-glucosamine as raw materials; and the health-cared preparation is prepared according to a certain weight ratio. The raw materials are combined together so that the effects generate synergic action, the absorption of the human body to the calcium is effectively promoted, and the bone conditions are improved. The product has the effects of tonifying the liver and kidney, strengthening the muscles and bones, supplementing the calcium source and improving the osteoporosis of the middle and old aged women.

Extracts of various species of the Moraceae family have estrogenic properties. For example, aqueous and ethanolic extracts of Ligustrum lucidum Ait. of the Oleaceae Family possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effects include estrogen response element (ERE) stimulation as well as tumor necrosis factor (TNF) repression. Methods are provided for treating climacteric symptoms, breast and/or uterine cancer, and osteoporosis.

The invention discloses a kit for juvenile osteoporosis detection. Through gene comparison, the fact that compared with a DKK1 gene in the normal people group, a juvenile form osteoporosis patient has the obvious mutant site is discovered, and the obvious mutant site is the 721 site. Through detecting the mutant site, particularly through the pair of provided specific primer pair, whether the people has the juvenile form osteoporosis symptom or not can be specifically identified. Compared with the prior art, the detection method has the advantages that the detection is convenient; accuracy and high speed are realized; the kit is suitable for being popularized and used.

This invention relates to formulations of bisphosphonates such as alendronate. The formulations taught herein enhance bioavailability of bisphosphonates and reduce esophageal and gastric ulcerations associated with them. Also taught herein are methods of preparing the formulations and their clinical use in the treatment of osteoporosis and other bone diseases.

The invention describes novel diuretic compounds comprising at least one heterocyclic nitric oxide donor group, or pharmaceutically acceptable salts thereof, and novel composition comprising at least one diuretic compound comprising at least one heterocyclic nitric oxide donor group, and optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one diuretic compound of the invention comprising at least one heterocyclic nitric oxide donor group, and optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidatives stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; and (p) treating sexual dysfunctions. The heterocyclic nitric oxide donors are preferably furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.

The invention of this application relates to compositions and methods for the treatment and/or prevention of osteoporosis; improving and/or enhancing bone formation; and prevention and/or reducing bone mineral density loss. More particularly, the invention relates to a composition comprising vitamin K, in any form and betacryptoxanthin. A further aspect of this invention is a composition comprising vitamin K, in any form, betacryptoxanthin, and/or vitamin D and/or calcium.

The present invention provides compositions and methods useful for treating, preventing or slowing the progression of ONJ and ORNJ. The invention provides for the use of PDGF in a pharmaceutically acceptable buffer in the preparation of a medicament useful for treating, preventing or slowing the progression of ONJ and ORNJ. The invention provides for the use of PDGF in a pharmaceutically acceptable buffer wherein the PDGF is disposed in a biocompatible matrix in the preparation of a medicament useful for treating, preventing or slowing the progression of ONJ and ORNJ. In one embodiment, a method for treating, preventing or slowing the progression of ONJ or ORNJ comprises providing a composition comprising a PDGF solution disposed in a biocompatible matrix and applying the composition to a desired site in the jaw. In another embodiment, a method for treating, preventing or slowing the progression of ONJ or ORNJ comprises providing a composition comprising a PDGF in a pharmaceutically acceptable buffer and applying the composition to a desired site in the jaw. The present invention also provides kits useful for treating, preventing or slowing the progression of ONJ and ORNJ.

The invention relates to a novel benzothiophene derivative and application thereof in preventive and/or treatment medicine for breast cancer and osteoporosis. The benzothiophene derivative is an ideal selective estrogen receptor modulator, can be used for treating or preventing various indications related to estrogen functions, and is particularly applicable to treating post-menopause breast cancer and osteoporosis. The compound has the advantages that oxidative metabolism is lowered, effective bioavailability is higher, and accordingly, dosage of the compound is little, tolerance of the compound is fine, and side effects are low.